Cyxone Future Growth

Future criteria checks 0/6

Cyxone's revenue and earnings are forecast to decline at 120% and 18.1% per annum respectively while EPS is expected to grow by 3.4% per annum.

Key information

-18.1%

Earnings growth rate

3.4%

EPS growth rate

Biotechs earnings growth	30.8%
Revenue growth rate	-120.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	27 Feb 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:4CX - Analysts future estimates and past financials data (SEK Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-39	-37	-37	1
12/31/2025	N/A	-38	-35	-35	1
12/31/2024	N/A	-28	-26	-26	1
12/31/2023	5	-23	-26	-19	N/A
9/30/2023	6	-18	-32	-18	N/A
6/30/2023	6	-23	-33	-21	N/A
3/31/2023	8	-32	-46	-36	N/A
12/31/2022	6	-42	-49	-41	N/A
9/30/2022	N/A	-54	-51	-50	N/A
6/30/2022	N/A	-54	-55	-54	N/A
3/31/2022	N/A	-53	-45	-44	N/A
12/31/2021	N/A	-45	-44	-43	N/A
9/30/2021	N/A	-43	-43	-43	N/A
6/30/2021	N/A	-45	-39	-44	N/A
3/31/2021	N/A	-47	-45	-45	N/A
12/31/2020	N/A	-49	-45	-45	N/A
9/30/2020	N/A	-46	-43	-43	N/A
6/30/2020	N/A	-46	-46	-41	N/A
3/31/2020	N/A	-39	-36	-36	N/A
12/31/2019	N/A	-35	-35	-35	N/A
9/30/2019	N/A	-47	-57	-43	N/A
6/30/2019	N/A	-39	-49	-36	N/A
3/31/2019	N/A	-36	-49	-35	N/A
12/31/2018	N/A	-32	-43	-30	N/A
9/30/2018	N/A	-14	-19	-13	N/A
6/30/2018	N/A	-11	-16	-10	N/A
3/31/2018	N/A	-10	-13	-7	N/A
12/31/2017	N/A	-9	-11	-5	N/A
9/30/2017	0	-7	N/A	-6	N/A
6/30/2017	N/A	-7	N/A	-8	N/A
3/31/2017	N/A	-5	N/A	-5	N/A
12/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	0	0	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 4CX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 4CX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 4CX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 4CX is forecast to have no revenue next year.

High Growth Revenue: 4CX is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 4CX's Return on Equity is forecast to be high in 3 years time

Cyxone Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Recent updates

Cyxone AB (publ) Announces Chief Executive Officer Changes

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

New major risk - Financial position

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Cyxone AB (publ) to Report Q4, 2024 Results on Feb 25, 2025

New major risk - Revenue and earnings growth

Cyxone AB (publ) to Report Q3, 2023 Results on Nov 21, 2023

Cyxone Announces CFO Changes

Cyxone AB (publ) Announces Board Changes

Cyxone AB (Publ) Receives Ethical and Regulatory Approval from Georgia to Conduct Clinical Phase 2B Study in RA

Cyxone AB (Publ) Advances the Patent Portfolio for Rabeximod

Cyxone AB (publ) to Report Fiscal Year 2023 Results on Feb 23, 2024

Cyxone AB (Publ) Appoints Carl-Magnus Högerkorp as Permanent CEO

Cyxone (publ) Receives Ethical and Regulatory Approval from Hungary to Start Clinical Phase 2b Study in RA

Cyxone AB (Publ) Announces That the Members of the Nomination Committee for Annual General Meeting 2023

Cyxone Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (publ) Receives Regulatory Approval to Start Clinical Phase 2B Study in RA

Cyxone AB (Publ) Appoints Erika Samuelsson as Chief Development Officer

Cyxone AB (Publ) Announces CFO Changes

Cyxone AB (publ) to Report Q3, 2022 Results on Oct 27, 2023

Cyxone Files Submission to Start Clinical Phase 2B Study in Poland and Georgia

Cyxone Receives Pre-IND Response from the US FDA regarding RA study

Cyxone (Publ) Files Regulatory Submission to Start Clinical Phase 2B Study with Rabeximod

Cyxone Announces Executive Changes

Cyxone AB Announces Promising T20k/Kora Combination Therapy Efficacy in Preclinical Therapeutic Model of MS

Safety Confirmation and Observed Trends in Covid-19 Study Build Further Confidence in Cyxone's Rheumatoid Arthritis Program

Cyxone (publ) Announces Resignation of Cornel Pater as Chief Medical Officer

Cyxone (publ) Reports Publication of Four Patent Applications Pertaining to its Drug Candidate Rabeximod

Cyxone (publ) Initiates Early Operations with Global Contract Research Organization to Conduct Phase 2B Trial in Rheumatoid Arthritis

Cyxone Files Patent Application with Potential to Extend Market Exclusivity of the Drug Candidate Rabeximod

Cyxone AB (Publ) Comments on the Covid-19 Study Results

Cyxone (Publ) Presents Top-Line Results from A Phase 2 Study of Rabeximod in Covid-19 Patients

Cyxone AB (Publ) Expects to Communicate Top-Line Results from A Recently Concluded Phase 2 Trial of Its Drug Candidate Rabeximod in Covid-19 Patients

CFO & Interim CEO Ola Skanung has left the company

Cyxone Announces Rabeximod in Covid-19 Phase 2 Trial Closed and Data to Be Reports in Third Quarter

Cyxone Explores Expanding into New Regions to Mitigate Potential Delay in Covid-19 Trial Completion

Chief Operating Officer has left the company

Cyxone Joins Forces with Leading Rheumatoid Arthritis Expert

Cyxone Initiates Feasibility Preclinical Studies to Optimize Path Forward for Multiple Sclerosis Drug Candidate T20K

Cyxone AB (publ) to Report Q4, 2021 Results on Feb 11, 2022

Cyxone (publ.) Reports First Covid-19 Patient Screened in Phase 2 Clinical Trial of Rabeximod

Cyxone AB (publ), Annual General Meeting, Jun 03, 2021

Cyxone AB (publ) Files an IND in the US with Rabeximod Following Positive Feed-Back from Pre-IND Meeting with the FDA

New 90-day low: €0.48

Cyxone AB (publ) Files Patent Application to Extend Exclusivity of Rabeximod

New 90-day low: €0.49

Cyxone Announces Expanded Plans for Rabeximod

New 90-day low: €0.50

Cyxone AB (Publ) Revises the Development Plan for Rabeximod

New 90-day high - €0.71

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies